This Multibagger Pharma Stock Secures Strategic Foothold in Europe — Is It Set for Massive Growth?

Pushkar Shinde
This Multibagger Pharma Stock Secures Strategic Foothold in Europe — Is It Set for Massive Growth?

Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams

Kwality Pharmaceuticals Limited (KPL) has achieved a significant milestone by entering the European market with its product Leuprorelin Acetate. The approval for its 11.25 mg injectable suspension was granted in Greece, marking KPL’s debut in Europe’s highly regulated pharmaceutical sector.

Validation Batches and Regular Supply

KPL is set to deliver the first three validation batches of Leuprorelin Acetate by December 2024. After conducting rigorous Quality Control Analysis, the company will commence regular supplies in January 2025. This development aligns with KPL’s strategy to broaden its footprint in high-demand markets.

DSIJ offers a service 'Tiny Treasure' with recommendations for Small-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here

Projected Revenue and Sales Forecast

This new contract development and manufacturing organization (CDMO) arrangement is projected to generate annual sales of approximately USD 3 million. Distribution is expected to start in the fourth quarter of the fiscal year 2024–2025. Additionally, KPL plans to extend its product line to include other strengths of Leuprorelin Acetate, bolstering revenue prospects.

Financial Performance: Q2 2024-2025

Revenue and Profit Growth

In Q2 2024-2025, KPL reported a revenue increase of 29.16 per cent year-over-year, reaching Rs 90.26 crore. On a quarterly basis, the revenue rose by 12.32 per cent, showcasing KPL’s robust market demand and operational efficiency.

Net Profits and Margins

KPL’s net profit surged by 35.74 per cent year-over-year to Rs 8.47 crore. However, the net profit margin showed a 9.8 per cent decline over the past three months, settling at 9.38 per cent. Despite this, overall growth indicates a positive outlook.

Comprehensive Product Portfolio

Kwality Pharma holds ANVISA and EU GMP certifications and boasts a portfolio of over 3,000 formulations. Covering 25+ therapeutic areas, the portfolio includes generic drugs, complex biologics, oncology treatments, and more. The company’s extensive product range underscores its commitment to quality in various dosage forms and therapeutic categories

Rate this article:
3.5

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary6-Nov, 2024

Mindshare6-Nov, 2024

Multibaggers6-Nov, 2024

Mindshare6-Nov, 2024

Bonus and Spilt Shares6-Nov, 2024

Knowledge

MF28-Oct, 2024

Personal Finance28-Oct, 2024

Technical23-Oct, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR